(A) the hematopoietic stem cell transplanted (HSCT) recipients only (B) both autologous and allogeneic transplanted recipients (C) both solid organ and.

Slides:

Advertisements

Similar presentations

Case Presentation Conference Children’s Hospital of New Orleans James M. Roth M.D. Evelyn Kluka M.D.

Advertisements

HAEMATOLOGY MODULE: LYMPHOMA Adult Medical-Surgical Nursing.

Hematopoietic stem cell transplantation

Bone Marrow Transplant in Oncology. Source Pathology  Treat Leukemia by chemotherapy  Regeneration of normal marrow  Chemotherapy alone cannot eliminate.

Blood and marrow stem cell transplantation A.Basi ADULT HEMATOLOGIST,ONCOLOGIST IRAN UNIVERSITY OF MEDICAL SCIENCES.

Hematopoietic Stem Cell Transplantation (HSCT) Overview Willis H Navarro, MD Medical Director, Transplant Services, NMDP Associate Clinical Professor,

POSTER TEMPLATE BY: Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning (RIC) Features of.

Doug Brutlag 2011 Genomics, Bioinformatics & Medicine Doug Brutlag Professor Emeritus of.

Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2010 CIBMTR Summary Slides SUM10_1.ppt.

Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2011 Summary Slides Worldwide SUM-WW11_1.ppt.

Chapter 19 Cancer and the Immune System Dr. Capers.

Adult Immunization 2010 Herpes Zoster (Shingles) Segment This material is in the public domain This information is valid as of May 25, 2010.

Post Transplant Lymphoproliferative Disorders (PTLD)

POSTER TEMPLATE BY: Features of Epstein Barr Virus (EBV) reactivation after reduced intensity conditioning (RIC) unrelated.

The Immune System u Widely dispersed system u Review of structure and function F located in marrow cavities of bones F yellow vs. red marrow F hematopoiesis.

WELCOME APPLICANTS! January 13, Epstein-Barr Virus  Identified in 1964 in Burkitt lymphoma  Lab technician became ill with mononucleosis EBV.

The sencond xiangya hospital,central south university

Treatment of B Cell Malignancies: Current and Emerging Strategies Thomas A. Rado, MD, PhD.

PTLD. PTLD: Post-transplant Lymphoproliferative Disorders.

Myeloproliferative Disorders (MPDs)

Lymphoproliferative disorders. Several clinical conditions in which lymphocytes are produced in excessive quantities ( Lymphocytosis) Lymphoma Malignant.

Bone marrow Transplant in Paediatric Haematology

HAPLOIDENTICAL STEM CELL TRANSPLANT

Hematopoietic Stem Cell Transplantation (HSCT)

Evidence of B Cell Immune Responses to Acute Lymphoblastic Leukemia in Murine Allogeneic Hematopoietic Stem Cell Transplantation Recipients Treated with.

HAEMATOPOIETIC STEM ELL TRANSPLANTATION (HSCT) A process in which abnormal, malignant, or non- functioning marrow cells are replaced with normal marrow.

Hematopoietic Stem Cell Transplantation in Australia and New Zealand,

Successful Treatment of Richter Transformation with Ibrutinib in a Patient with Chronic Lymphocytic Leukemia following Allogeneic Hematopoietic Stem Cell.

Interferon-α: A Potentially Effective Treatment for Minimal Residual Disease in Acute Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic.

EBMT Activity Survey Teams Patients Transplants

Trend, Risk Factors and Outcome of Thrombotic Microangiopathy in Pediatric Hematopoietic Stem Cell Transplant Recipients: A Multi-Institutional Review

HS 4160 Critical Scientific Analysis

Survival in a Recent Cohort of Mechanically Ventilated Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients Josephus P.J. van Gestel,

EBMT Activity Survey Teams 39,313 Patients 43,636 Transplants

EBMT Activity Survey Teams Patients Transplants

Successful Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant in an Acute Leukemia Patient With Chemotherapy-Induced Marrow Aplasia and Progressive.

Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.

Humoral Immune Reconstitution Kinetics after Allogeneic Hematopoietic Stem Cell Transplantation in Children: A Maturation Block of IgM Memory B Cells.

by Jayesh Mehta Blood Volume 112(2): July 15, 2008

Survival in a Recent Cohort of Mechanically Ventilated Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients Josephus P.J. van Gestel,

Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma:

Timing for HCT Consultation

Cord blood transplantation and stem cell regenerative potential

Letermovir(Prevymis™) Guidelines for Inpatient Use

CMV in the HSCT Recipient

Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.

Chronic Kidney Disease in Long-Term Survivors after Allogeneic Hematopoietic Stem Cell Transplantation: Retrospective Analysis at a Single Institute

LONG TERM Outcomes of Pediatric Patients with Malignant and NON-Malignant Disorders Receiving Α/Β T-CELL Depleted HLA-Haploidentical Hematopoietic STEM.

Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.

Controversies in Lymphoma: The Role of Hematopoietic Cell Transplantation for Mantle Cell Lymphoma and Peripheral T Cell Lymphoma Peter Dreger, Ginna.

Lymphocyte Subset Recovery and Outcome after Autologous Hematopoietic Stem Cell Transplantation for Plasma Cell Myeloma Jessica Rueff, Michael Medinger,

JAK2 INHIBITORS AND ALLOGRAFTING

Favorable Outcomes in Patients Surviving 5 or More Years after Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies Robert.

Epidemiology, Management, and Outcome of Invasive Fungal Disease in Patients Undergoing Hematopoietic Stem Cell Transplantation in China: A Multicenter.

Protective Immunity Transferred by Infusion of Cytomegalovirus-Specific CD8+ T Cells within Donor Grafts: Its Associations with Cytomegalovirus Reactivation.

Polymorphisms in Genes That Regulate Cyclosporine Metabolism Affect Cyclosporine Blood Levels and Clinical Outcomes in Patients Who Receive Allogeneic.

Disparity in Survival Outcome after Hematopoietic Stem Cell Transplantation for Hematologic Malignancies According to Area of Primary Residence Keshav.

Shigeo Fuji, Hermann Einsele, Bipin N. Savani, Markus Kapp

Clinical Endpoints in Allogeneic Hematopoietic Stem Cell Transplantation Studies: The Cost of Freedom Haesook T. Kim, Philippe Armand Biology of Blood.

Introduction. Title: Activities and Outcomes of Hematopoietic Cell Transplantation in Japan.

Gerard Socié, K. Scott Baker, Smita Bhatia

Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD–Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-

Clinical Lymphoma, Myeloma and Leukemia

Yuri Fedoriw, T. Danielle Samulski, Allison M. Deal, Cherie H

Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected.

Prospective Study of the Incidence, Clinical Features, and Outcome of Symptomatic Upper and Lower Respiratory Tract Infections by Respiratory Viruses.

Hematopoietic Stem Cell Transplantation in Australia and New Zealand,

William Berquist, MD Gastrointestinal Endoscopy

Hematopoietic stem cell transplantation in HCV-infected patients

Presentation transcript:

(A) the hematopoietic stem cell transplanted (HSCT) recipients only (B) both autologous and allogeneic transplanted recipients (C) both solid organ and hematopoietic allograft (D) None of above

(A) malignant lymphoid neoplasms only (B) benign or malignant lymphoproliferative disorder (C) indolent B-cell lymphomas (D) aggressive B-cell lymphomas only

(A) in HSCT allografts are exclusively donor origin (B) in solid organ allogarfts are most donor origin (C) occurring in the HSCT recipients most are limited disease (D) more frequent occurs in the HSCT recipients than in the solid organ transplanted ones

(A) universally is Epstein-Barr virus (EBV) positive (B) in children behaves poorer outcome (C) correlates with the destruction of recipient’s immunity and EBV infection/reactivation (D) frequently involves in the bone marrow

(A) Anti-viral therapy is effective (B) Preemptive therapy with Rituximab is promising (C) Rutuximab is also effective in CD20- negative patients (D) Reduction of immunosuppression (RIS) is no longer beneficial

(A) the hematopoietic stem cell transplanted (HSCT) recipients only (B) both autologous and allogeneic transplanted recipients (C) both solid organ and hematopoietic allograft (D) None of above

(A) malignant lymphoid neoplasms only (B) benign or malignant lymphoproliferative disorder (C) indolent B-cell lymphomas (D) aggressive B-cell lymphomas only

(A) in HSCT allografts are exclusively donor origin (B) in solid organ allogarfts are most donor origin (C) occurring in the HSCT recipients most are limited disease (D) more frequent occurs in the HSCT recipients than in the solid organ transplanted ones

(A) universally is Epstein-Barr virus (EBV) positive (B) in children behaves poorer outcome (C) correlates with the destruction of recipient’s immunity and EBV infection/reactivation (D) frequently involves in the bone marrow

(A) Anti-viral therapy is effective (B) Preemptive therapy with Rituximab is promising (C) Rutuximab is also effective in CD20- negative patients (D) Reduction of immunosuppression (RIS) is no longer beneficial